JointHealth™ express January 28, 2013
Let BC PharmaCare hear “Your Voice”
People who live with arthritis, particularly those with inflammatory types and whose immune systems are suppressed, may be more susceptible to bacteria such as Clostridium difficile (C. difficile) while in hospital for surgery or a medical emergency related to their arthritis.
This bacterium causes an infection of the lining of the colon, which can result in painful and severe diarrhea.
Do you live with autoimmune arthritis and have gotten the serious infection, C. difficile, while you were in the hospital having your disease treated? Do you care for someone who has experienced this or does your organization represent people who have?
By filling out a questionnaire on a website called Your Voice, you can provide feedback to British Columbia’s Ministry of Health about fidaxomicin (Dificid®), which is a medication that kills C. difficile.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
It is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for.
Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
Or, email us your input at feedback@jointhealth.org or call us 604-974-1366 so that we can send it in on your behalf. Please provide your input to us by Wednesday, January 30 so that we may submit the questionnaire in time for the deadline.
Let BC PharmaCare hear “Your Voice”
People who live with arthritis, particularly those with inflammatory types and whose immune systems are suppressed, may be more susceptible to bacteria such as Clostridium difficile (C. difficile) while in hospital for surgery or a medical emergency related to their arthritis.
This bacterium causes an infection of the lining of the colon, which can result in painful and severe diarrhea.
Do you live with autoimmune arthritis and have gotten the serious infection, C. difficile, while you were in the hospital having your disease treated? Do you care for someone who has experienced this or does your organization represent people who have?
By filling out a questionnaire on a website called Your Voice, you can provide feedback to British Columbia’s Ministry of Health about fidaxomicin (Dificid®), which is a medication that kills C. difficile.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
It is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for.
Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
- To view the information sheet for fidaxomicin: click here
- For the Patient Questionnaire: click here
- For the Caregiver Questionnaire: click here
- For the Patient Group Questionnaire: click here. (Patient groups are required to register their name with the Ministry of Health before making their submission.)
Or, email us your input at feedback@jointhealth.org or call us 604-974-1366 so that we can send it in on your behalf. Please provide your input to us by Wednesday, January 30 so that we may submit the questionnaire in time for the deadline.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.